Heart Fail Clin. 2023 Apr;19(2):213-220. doi: 10.1016/j.hfc.2022.08.008.
ABSTRACT
COVID-19 infection triggers a heightened inflammatory response which in turn, increases thrombosis and thromboembolism. Microvascular thrombosis has been detected in various tissue beds which may account for some of the multi-system organ dysfunction associated with COVID-19. Additional research is needed to understand which prophylactic and therapeutic drug regimens are best for the prevention and treatment of thrombotic complications of COVID-19.
PMID:36863813 | DOI:10.1016/j.hfc.2022.08.008